www-nasdaq-com-38.html
Novo Annual Review 2016
39 / 71
trade sales and
initial
public
offerings adaptimmune initial public offering in 2015 aerie pharmaceuticals initial public offering in 2014 akebia therapeutics initial public offering in 2014 alder biopharmaceuticals initial public offering in 2014 alios biopharma acquired
by johnson & johnson amira pharmaceuticals acquired by bristol-myers squibb biomimetic therapeutics acquired by wright medical group elevation pharmaceuticals acquired by sunovion pharmaceuticals funxional therapeutics sold lead asset to boehringer ingelheim foldrx pharmaceuticals acquired by pfizer gloucester pharmaceuticals acquired by celgene insound medical acquired by sonova holding intersect ent initial public offering in 2014 neomend acquired by c r bard nevro initial public offering in 2014 novexel acquired by astrazeneca otonomy initial public offering in 2014 protein forest acquired by proteinsimple proteinsimple acquired by techne corporation ptc therapeutics initial public offering in 2013 santaris pharma acquired by roche sapphire therapeutics acquired by helsinn healthcare spinifex pharmaceuticals acquired by novartis synosia therapeutics acquired by biotie therapies tetraphase pharmaceuticals initial public offering in 2013 thiakis acquired by wyeth pharmaceuticals tobira therapeutics initial public offering in 2015 tokai pharmaceuticals initial public offering in 2014 zymogenetics acquired by bristol-myers squibb zs pharma initial public offering in 2014 selected exits 2007 ?2016 a b e g f z i n o p s t n 39 novo ventures
novo-science-2016-40.html
